About Protocadherin-9
Protocadherin-9 (PCDH9) is a protein
from Homo sapiens identified by UniProt accession
Q9HC56, 1237 residues long.
MolForge cross-references it against 0 known binders and
129 disease associations.
Target properties
| Protein name | Protocadherin-9 |
|---|
| UniProt accession | Q9HC56 |
|---|
| Gene | PCDH9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1237 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (129)
Diseases linked to this target (Open Targets).
- body mass index · score 0.45
- blood protein measurement · score 0.45
- depressive symptom measurement · score 0.44
- neuroticism measurement · score 0.43
- unipolar depression · score 0.43
- self reported educational attainment · score 0.43
- overall survival · score 0.42
- smoking status measurement · score 0.41
- wellbeing measurement · score 0.39
- smoking initiation · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9HC56-F1 | alphafold | PREDICTED | 67.84 | — |
Amino-acid sequence (1237 residues)
MDLRDFYLLA ALIACLRLDS AIAQELIYTI REELPENVPI GNIPKDLNIS HINAATGTSA SLVYRLVSKA GDAPLVKVSS STGEIFTTSN RIDREKLCAG ASYAEENECF FELEVVILPN DFFRLIKIKI IVKDTNDNAP MFPSPVINIS IPENTLINSR FPIPSATDPD TGFNGVQHYE LLNGQSVFGL DIVETPEGEK WPQLIVQQNL DREQKDTYVM KIKVEDGGTP QKSSTAILQV TVSDVNDNRP VFKEGQVEVH IPENAPVGTS VIQLHATDAD IGSNAEIRYI FGAQVAPATK RLFALNNTTG LITVQRSLDR EETAIHKVTV LASDGSSTPA RATVTINVTD VNDNPPNIDL RYIISPINGT VYLSEKDPVN TKIALITVSD KDTDVNGKVI CFIEREVPFH LKAVYDNQYL LETSSLLDYE GTKEFSFKIV ASDSGKPSLN QTALVRVKLE DENDNPPIFN QPVIELSVSE NNRRGLYLTT ISATDEDSGK NADIVYQLGP NASFFDLDRK TGVLTASRVF DREEQERFIF TVTARDNGTP PLQSQAAVIV TVLDENDNSP KFTHNHFQFF VSENLPKYST VGVITVTDAD AGENKAVTLS ILNDNDNFVL DPYSGVIKSN VSFDREQQSS YTFDVKATDG GQPPRSSTAK VTINVMDVND NSPVVISPPS NTSFKLVPLS AIPGSVVAEV FAVDVDTGMN AELKYTIVSG NNKGLFRIDP VTGNITLEEK PAPTDVGLHR LVVNISDLGY PKSLHTLVLV FLYVNDTAGN ASYIYDLIRR TMETPLDRNI GDSSQPYQNE DYLTIMIAII AGAMVVIVVI FVTVLVRCRH ASRFKAAQRS KQGAEWMSPN QENKQNKKKK RKKRKSPKSS LLNFVTIEES KPDDAVHEPI NGTISLPAEL EEQSIGRFDW GPAPPTTFKP NSPDLAKHYK SASPQPAFHL KPDTPVSVKK HHVIQELPLD NTFVGGCDTL SKRSSTSSDH FSASECSSQG GFKTKGPLHT RQCNSHSKSD NIPVTPQKCP SSTGFHIQEN EESHYESQRR VTFHLPDGSQ ESCSDSGLGD HEPVGSGTLI SHPLPLVQPQ DEFYDQASPD KRTEADGNSD PNSDGPLGPR GLAEATEMCT QECLVLGHSD NCWMPPGLGP YQHPKSPLST FAPQKEWVKK DKLVNGHTLT RAWKEDSNRN QFNDRKQYGS NEGHFNNGSH MTDIPLANLK SYKQAGGATE SPKEHQL
Explore Protocadherin-9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets